The increase in human leukocyte adenosine 3':5'-cyclic monophosphate (cyclic AMP) levels seen in response to various substances was markedly potentiated by colchicine and other agents that affect microtubule assembly. Addition of dI-isoproterenol (2 AiM) or prostaglandin El (10 ttM), together with the phosphodiesterase inhibitor isobutylmethylxanthine (1 mM), caused a much greater increase in cyclic AMP in colchicine-pretreated cells tan in control cells. With isoproterenol (2 MM) plus isobutylmethylxanthine (1 mM), cyclic AMP levels rose about 3fold but, in combination with colchicine, these drugs caused a more than 15-fold increase in cyclic AMP. The effects of colchicine were both time-and dose-dependent; they could be seen'within 1 min after addition of colchichme or at concentrations as low as 10 nM. In addition to its potentiation of hormonally induced increases in cyclic AMP levels, colchicine also potentiated the effect of isobutylmethylxanthine alone on leukocyte cyclic AMP levels. Vinblastine, vincristine, podophyllotoxin, and oncodazole all had effects similar to those of colchicine but blmicolchicine did not. The data suggest that cytoplasmic nticrbtubules interact with the leukocyte plasma membrane to impose constraints on the expression of hormone-sensitive adenylate cyclase; the therapeutic effects of colchicine may depend in part upon the relaxation of such constraints. Moreover, the synergism described here between colchicine-like agents and hormones is of potential therapeutic importanceiln clinical conditions in which either alkaloid or hormone has been useful separately.
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I
The cyclic nucleotide levels of human leukocytes (both granulocytes and mononuclear cells) are controlled by a number of hormones and pharmacological agents (1) (2) (3) (4) (5) . f3-Adrenergic agonists (isoproterenol, epinephrine), histamine, and prostaglandin E1 (PGE1) all raise adenosine 3':5'-cyclic monophosphate (cyclic AMP) levels in these cells; the muscarinic cholinergic agonists (acetylcholine, carbamylcholine) raise cyclic GMP levels. In granulocytes, a functional significance of cyclic nucleotides has been suggested by experiments showing that increases in cyclic AMP inhibit the degranulation of lysosomes that normally accompanies phagocytosis, whereas increases in cyclic GMP enhance degranulation (2, 3, 5, 6) . Colchicine and vinblastine, agents that cause the disappearance of cytoplasmic microtubules by preventing their assembly (7-10), also inhibit degranulation (6, (11) (12) (13) ; it is through this inhibition of microtubule assembly, with consequent effects on microtubuleassociated functions, that colchicine is thought to exert its therapeutic anti-inflammatory action in acute gouty arthritis and other disorders (14) . We now report that colchicine and other agents that interfere with microtubule assembly increase cyclic AMP levels in human leukocytes and potentiate the effects of hormones on cyclic AMP levels in these cells.
METHODS
Leukocytes were obtained from freshly drawn, heparinized blood from healthy, adult donors by dextran sedimentation and hypotonic lysis of residual erythrocytes as described (11) . The leukocytes were resuspended in 123.5 mM NaCl/5.0 mM KCI/0.3 mM MgCl2/0.5 mM CaCl2/16.0 mM sodium phosphate/heparin, 1 unit/ml at pH 7.4. Differential counts were approximately 70-80% neutrophils and 20-30% lymphocytes with 1-4% monocytes and eosinophils. Platelets were rare. All manipulations were carried out in siliconized glass or plastic tubes or flasks.
Cell suspensions (I to 5 X 107 cells per ml) were preincubated with colchicine or other drugs, at 370 in a Dubnoff metabolic shaker. Aliquots (200 pl) of the cell suspension were then transferred to plastic tubes, and incubation was continued for an additional 2 min in the presence of other test substances. The reaction was terminated by placing the tubes in a boiling water bath for 5 min. Then, 300 ,l of water was added to each tube and the samples were frozen. After thawing, the samples were centrifuged (900 X g for 10 min) to remove particulate material, and triplicate aliquots were withdrawn (10-100 1d) for cyclic AMP determination. Cyclic AMP was measured by the isotope dilution assay of Brown et al. (15) .
Lumicolchicine was prepared by ultraviolet irradiation of colchicine solutions as described (16 
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The effect of preincubation with colchicine was also tested on the isoproterenol-induced increase in cyclic AMP level ( those observed in the presence of iBuMeXan alone. This synergism of-colchicine and dl-isoproterenol developed over a narrow colchicine concentration range (2 X 10-7 to 1 X 10-M), similar to that effective in the absence of isoproterenol.
As shown in Table 1 , a phosphodiesterase inhibitor was required for detecting maximal effects of colchicine and dl-isoproterenol, either alone or in combination.
The time dependence of the effect of colchicine on leukocyte cyclic AMP level is shown in Fig. 3 . At the lowest colchicine concentration shown (I0-7 M), there was no significant effect before 60 min of preincubation, but there was-a 3fold increase at 120 min. With the highest concentration shown (10-6 M), there was a half-maximal increase in cyclic AMP level within 20 (10 ,gM) and incubation time (30 min), was without effect. Cytochalasin B, an agent known to interfere with microfilament structure, had little or no effect on either resting or hormonally stimulated cyclic AMP levels.
It has been reported that colchicine may stimulate prostaglandin release from cultured cells (19) . It is unlikely that this effect might account for the increased cyclic AMP levels observed in colchicine-treated leukocytes, because neither indomethacin (0. 1 mM) nor aspirin (1 mM), both of which are potent inhibitors of prostaglandin synthesis, had any effect on the colchicine-mediated stimulation of cyclic AMP levels, even Cells were preincubated for 30 min at 370 in the presence of the indicated drugs. Incubation was then carried out for an additional 2 min in the presence of iBuMeXan alone (control) or plus dl-isoproterenol. The final concentrations of iBuMeXan and of dl-isoproterenol were 1 mM and 2 MM, respectively. Cyclic AMP was determined as described in the text. Dimethyl sulfoxide was used to dissolve oncodazole, podophyllotoxin, and cytochalasin B. Ethanol was used to dissolve indomethacin and aspirin. These solvents were present at a final concentration of 1% in incubations with the above drugs; neither dimethyl sulfoxide (1%) nor ethanol (1%) affected cyclic AMP levels under any of the experimental conditions tested. * Mean i SEM (n = 3).
when present during the 30-min preincubation period. Hydrocortisone (1 mM), gold sodium thiomalate (1.3 mM), and chloroquine (10 AuM) also had no effect.
DISCUSSION
The data presented show that colchicine and other agents that interfere with microtubule assembly cause an increase in human leukocyte cyclic AMP levels; these agents also potentiate 0B-adrenergic and PGE1 stimulation of cyclic AMP levels. These effects of colchicine could be manifested through an increase in the rate of production of cyclic AMP or a decrease in its rate of hydrolysis. The latter possibility, however, seems unlikely, because a phosphodiesterase inhibitor (iBuMeXan) is required for the effects of colchicine to be detected; preincubation of the cells with colchicine alone is relatively ineffective in stimulating cyclic AMP levels, in either the absence or the presence of hormones. Therefore, it would appear that colchicine acts to increase adenylate cyclase activity. Such an increase might be accomplished in any of several ways: (i) the availability of substrate (ATP) might be increased; (ii) the intrinsic turnover number of the enzyme might be increased; (iii) the number of active adenylate cyclase molecules might be increased; (iv) the hormone receptor-adenylate cyclase interaction might be made more efficient; or (v) the guanyl nucleotide binding site or guanyl nucleotide metabolism might be affected.
The data shown in Table 2 indicate that other known inhibitors of microtubule assembly (vinblastine, vincristine, oncodazole, and podophyllotoxin) have effects similar to those of colchicine, whereas lumicolchicine, which does not inhibit assembly, has no such effect. These chemically distinct agents have in common the ability to bind to tubulin; that they do not all bind at the same site is further evidence for their specificity of action (17, 20, 21) . It thus seems probable that the effects of colchicine are a result of its inhibition of tcrotubule Moreover, the effects of preincubation with colchicine do not persist after the cells are broken, nor does colchicine affect directly either basal or hormone-stimulated adenylate cyclase activity in leukocyte membrane preparations (data not shown), even though these preparations respond readily to the hormones themselves, suggesting that the colchicine effect on cyclic AMP levels is a result of its interaction with cytoplasmic, rather than membrane-associated, tubulin. It has been suggested that colchicine-sensitive cytoplasmic structures (presumably microtubules) may interact with the cell membrane in such a way as to place constraints on the mobility of certain receptors (22) (23) (24) (25) . Previous work has involved primarily lectin-binding receptors. It is interesting to speculate on how such an interaction might be responsible for effects on receptor-mediated changes in cyclic AMP reported here. As shown in Fig. 4 , colchicine increased both basal and hormone-stimulated levels of cyclic AMP, and we have interpreted these effects as being due to an increase in adenylate cyclase activity. Current evidence suggests that hormone receptors and adenylate cyclase are separate entities (26) and that the receptor interacts with the adenylate cyclase to cause activation (27) ; the apparent affinity of this interaction is greatly enhanced when the receptor is occupied by the appropriate hormone. Thus, the time of interaction between receptor and cyclase will be longer when the receptor is occupied. In order to facilitate discussion of this point, we can express the total adenylate cyclase activity as follows:
(nac,-Tac) + (Nr-ac tr-ac Tr-ac) (Nrh-ac' trh ac' Trh-a) in which n, = (28) . Other antimitotic agents have effects similar to those of colchicine (29) , whereas lumicolchicine does not (30) .
The lowest concentration of colchicine tested in the present study (10-8 M) , which was effective after a 3-hr incubation, is attained in plasma with doses of the drug used therapeutically (31) . If functional synergism between colchicine-like drugs and those hormones whose effects are mediated through cyclic AMP is a more general phenomenon, then appropriate combinations of agents may provide increased therapeutic power in situations in which either class of drugs has proven useful but often not ideal when used alone-for example, colchicine, used as an anti-inflammatory or antimitotic agent, and fl-adrenergic agonists, used in allergic and asthmatic disorders.
